Aliases:This biomarker is also known as:
- t cell-specific protein P228,
- eosinophil chemotactic cytokine,
- beta-chemokine RANTES,
- Small-inducible cytokine A5,
- chemokine (C-C motif) ligand 5,
- regulated upon activation, normally T-expressed, and presumably secreted,
- small-inducible cytokine A5,
- T-cell specific protein p288,
- small inducible cytokine A5 (RANTES),
- small inducible cytokine subfamily A (Cys-Cys), member 5,
- C-C motif chemokine 5,
- Eosinophil chemotactic cytokine,
- T cell-specific protein P228,
- T-cell-specific protein RANTES,
From NCBI Gene: This gene is one of several chemokine genes clustered on the q-arm of chromosome 17. Chemokines form a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of the N-terminal cysteine residues of the mature peptide. This chemokine, a member of the CC subfamily, functions as a chemoattractant for blood monocytes, memory T helper cells and eosinophils. It causes the release of histamine from basophils and activates eosinophils. This cytokine is one of the major HIV-suppressive factors produced by CD8+ cells. It functions as one of the natural ligands for the chemokine receptor chemokine (C-C motif) receptor 5 (CCR5), and it suppresses in vitro replication of the R5 strains of HIV-1, which use CCR5 as a coreceptor. Alternative splicing results in multiple transcript variants that encode different isoforms. [provided by RefSeq, Jul 2013]
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
The chemokine CCL5 (RANTES), a major monocyte chemoattractant expressed by breast tumor cells, has been implicated in the progression of breast cancer.
CCL5 (RANTES) was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- HGNC entry for CCL5 from Genenames
- KEGG entry for CCL5 from Genome.jp
- Entrez entry for CCL5 all NCBI Databasese
- Human GEO Profiles for CCL5 from NCBI GEO Profiles
- Human Geo Datasets containing term CCL5 from NCBI GEO Datasets
- GWAS Study Datasets containing gene CCL5 from GWAS
- Human Single Nucleotide Polymorphisms info for CCL5
- Human Gene(s) with 'CCL5' as Gene Name/Alias
- Human Gene RefSeq for CCL5 from NCBI
- GeneCards entry for human CCL5
- UniProtKB/Swiss-Prot entry for CCL5 from Uniprot
- Human Protein RefSeq for CCL5 from NCBI
- FDA web page describing approval of CCL5
|UniProt Accession #:||P13501|
|Mutated Sites Count:||12|
|Associated Pubmed ID Count||2|
|Affected Protein Function Sites Count:||4|